Lupin Arm Ink Agreement to Acquire VISUfarma for €190 Million; Share Price Surges

Lupin Limited has announced a definitive agreement to acquire VISUfarma B.V., an Amsterdam-based speciality pharmaceutical firm, in a transaction valued at €190 million (Enterprise Value). 

The move, routed through Lupin’s wholly owned subsidiary Nanomi B.V., underscores the Indian pharma major’s ambition to scale its ophthalmology footprint and deepen its presence in the European market.

Transaction Scope and Terms

The acquisition, structured as a 100% stake purchase, will be settled in cash from Lupin’s existing reserves and remains subject to approvals from national FDI authorities in Germany and regulatory notification in Spain. Completion is targeted by the end of CY2025. 

VISUfarma, with subsidiaries in the UK and Italy, recorded turnover of €48.1 million and a net worth of €134.6 million in CY2024. Its portfolio of over 60 branded products spans glaucoma, dry eye, eyelid hygiene, retinal care, blepharitis, and nutraceuticals.

VISUfarma’s commercial network extends across Italy, the UK, Spain, Germany, and France, with estimated revenues of €54 million for CY2025. Founded in 2016, the company has become a pan-European ophthalmology leader, evolving from its origins in Italy into a broad-based operator.

Strategic Fit for Lupin and Advisors to the Deal

The acquisition of VISUfarma marks an important strategic step for Lupin, enhancing its speciality portfolio and particularly strengthening its presence in ophthalmology. This therapeutic area continues to show strong growth globally, driven by ageing populations, the increasing prevalence of diabetes-related eye disorders, and a growing focus on preventive care. 

The deal is expected to be immediately accretive to both sales and EBITDA margins, while also aligning with Lupin’s long-term objective of building a robust speciality business across Europe, India, Mexico, and other international markets, with further opportunities for expansion in Southeast Asia.

Read More: Sun Pharma, Lupin & More Indian Pharma Stocks in Focus as Trump Announces 100% Tariffs!

Lupin Share Price Performance 

As of September 29, 2025, at 11:40 AM, Lupin share price is trading at ₹1,939.30 per share, reflecting a gain of 1.02% from the previous closing price. Over the past month, the stock has gained by 2.34%.

Conclusion

The €190 million VISUfarma acquisition highlights Lupin’s determination to accelerate its speciality play in ophthalmology and strengthen its foothold in Europe. With a robust portfolio, pan-European reach, and synergy potential, the deal positions Lupin to deliver growth in one of the most resilient therapeutic segments while advancing its global specialty strategy.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.